This is the most common misunderstanding in menopausal hair loss, and it's the one that costs women years of wasted hope.

HRT replaces the oestrogen your body has stopped producing. And oestrogen was, among other things, the thing protecting your hair follicles from DHT — the hormone responsible for follicle miniaturisation. So logic says: put oestrogen back in, hair recovers.

Here's the problem. HRT repairs the hormonal environment. It does not repair the follicle itself. Once DHT has spent months or years constricting the tiny blood vessels that feed your follicles, those follicles are starved of the oxygen and nutrients they need to grow hair. Restoring oestrogen slows further damage — but it cannot reverse starvation that's already happened.

This is why so many women start HRT, wait 6, 9, 12 months, and report exactly the same or worse thinning. The follicle needs targeted reactivation — not just a hormonal reset.

Biotin is almost certainly the most widely sold — and most misunderstood — hair supplement on the market.

Here's what biotin actually does: it supports keratin synthesis in the hair shaft. It makes existing hair look better. Shinier. Less brittle. More resilient. For women with a nutrient deficiency, it can even modestly reduce breakage.

What it does not do: grow new hair. Because the hair shaft is dead. It's already been produced. If you want to address hair loss — fewer hairs, thinner hairs, a wider parting, thinning temples — you need to work at the follicle. That's the living structure inside your scalp, 2–4mm deep, that produces the shaft.

Biotin does not reach the follicle in meaningful concentration. It has no known mechanism for reversing follicle miniaturisation. And it has no DHT-blocking activity whatsoever. For menopausal hair loss, it is close to entirely irrelevant.

Walk into any pharmacy and you'll find an entire wall dedicated to "anti-thinning," "volumising," and "hair loss" shampoos. Some of them contain ingredients — zinc pyrithione, ketoconazole, saw palmetto — that do have clinical evidence behind them.

The problem is contact time.

A shampoo sits on your scalp for 60 to 90 seconds. Then it's rinsed away. For any active compound to reach a hair follicle — which sits 2–4mm beneath the scalp surface — it needs to penetrate the skin barrier, survive the rinse, and remain in therapeutic concentration long enough to work. A wash-off product cannot do any of this.

This is not a secret in dermatology. Trichologists have known for years that leave-on formulations are the only delivery system that can put actives where they're needed. Shampoos keep getting made and sold because they're easy to produce, easy to market, and easy to buy repeatedly. They generate comfort, not results.

Minoxidil works by forcing blood vessels to widen, increasing blood flow to the follicle. For many women it produces genuinely visible results — reduced shedding, some regrowth. It is the only non-prescription topical with solid clinical data behind it.

But for menopausal hair loss specifically, it has a fundamental limitation: it does not block DHT. It doesn't address the hormonal mechanism at all. It forces circulation through vessels that DHT is simultaneously working to constrict. The moment you stop, the underlying mechanism reasserts itself — and the resulting shedding is often worse than before you started.

This traps many women in a dependency they never signed up for. Side effects — unwanted facial hair, scalp irritation, reported heart palpitations in some cases — make them want to stop. But stopping triggers accelerated loss. It's a loop with no clean exit.

Almost every major hair loss treatment on the market — from DHT-blocking shampoos to prescription finasteride to OTC topicals — was developed primarily for male androgenic alopecia, or for temporary telogen effluvium (post-stress or post-illness shedding).

Neither maps onto menopausal AGA. The hormonal substrate is different. The pattern of loss is different. The speed of progression is different. And critically, the required treatment mechanism is different — because menopause-driven hair loss involves a specific combination of DHT assault, follicle microcirculation failure, and the loss of oestrogen's protective scaffolding.

Products designed for men need to account for none of this. So they don't. And women spend years trying solutions that were never built for their biology — and conclude the problem is unfixable.

Oestrogen does more than protect follicles from DHT. It maintains the structural integrity of the scalp itself: the hydration, elasticity, and dermal thickness of the tissue the follicle lives in. When oestrogen declines, the scalp becomes drier, less supple, and less able to deliver nutrients to follicles via the dermal papilla.

Meanwhile, DHT builds up in sebum on the scalp surface, creating a micro-environment where follicles are being attacked from above and starved from below simultaneously. Regular washing helps — but it's a stopgap, not a solution.

What the follicle actually needs is a restored microenvironment: adequate hydration in the dermal layer, unobstructed capillary flow, and a barrier against the DHT accumulation that's compressing follicle structure from the outside in.

The women who have successfully reversed menopausal hair thinning share one thing in common: they stopped treating the symptom and started targeting the mechanism. Specifically:

1. Block DHT at the follicle level — not systemically, but topically, directly where the follicle lives. Saw palmetto extract, applied to the scalp in concentrated leave-on form, inhibits 5-alpha-reductase — the enzyme that converts testosterone to DHT at the follicle — without the systemic side effects of pharmaceutical DHT blockers.

2. Restore microcirculation to the starved follicle — topical caffeine and rosemary extract have both demonstrated vasodilatory effects in peer-reviewed studies, with topical rosemary performing comparably to 2% minoxidil in a 2023 Journal of Dermatology study over 6 months.

3. Reactivate follicle stem cells directly — Redensyl, a patented compound derived from dihydroquercetin, targets the LRIG1 stem cells in the outer root sheath of the follicle — the cells responsible for triggering the anagen growth phase. In clinical trials, Redensyl increased anagen hairs by 214% vs placebo over 3 months and reduced hair loss by 17%.

4. Restore the scalp microenvironment — hyaluronic acid in a scalp-grade formula rebuilds dermal hydration and follicle-surrounding tissue that oestrogen decline has degraded.

This is the four-part protocol that the Mellenza Hair Growth Spray was built around — the first formulation developed specifically for the hormonal hair loss profile of women in perimenopause and menopause.